评估WHO GLASS目标细菌耐药感染负担研究的方法学质量
该研究检索1950年至2019年3月文献,评估WHO GLASS监测的优先耐药病原体所致感染临床影响研究的方法学质量。
要点
- 多数研究为高收入国家回顾性单中心队列,代表性有限。
- 健康影响多仅报告全因死亡率,评估时点异质。
- 缺乏健康状态定义和病程数据,无法计算DALY。
核心结论
- 迫切需要改进耐药监测数据和队列研究的协调性、代表性及质量,以确定耐药归因死亡和疾病负担。
主要发现
- 健康影响主要限于全因死亡率(128项,45%),评估时点存在异质性;归因住院时长很少校正感染前入院时间,少数研究有足够随访评估长期后遗症。
- 对混杂因素的校正总体上有显著改善,但健康状态定义和疾病持续时间数据普遍缺乏,阻碍DALY计算。
临床怎么用
- 解读耐药感染负担研究时需注意其多来自高收入国家回顾性单中心数据,外推需谨慎。
- 临床研究中应规范记录健康状态定义和病程,以便计算DALY支持疾病负担评估。
局限性
- 研究多来自高收入国家、回顾性、单中心设计,代表性和内部真实性受限。
- 健康影响多仅报告全因死亡率,评估时点异质,归因住院时长未充分校正感染前入院时间。
- 缺乏健康状态定义和病程数据,无法计算DALY。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The health impact of antimicrobial resistance (AMR) has not been included in the Global Burden of Disease (GBD) report, as reliable data have been lacking. AMR burden estimates have been derived from models combining incidence and/or prevalence data from national and/or international surveillance systems and mortality estimates from clinical studies. Depending on utilized empirical data, statistical methodology and applied endpoints, the validity and reliability of results can differ substantially. OBJECTIVES: We assessed comprehensiveness, and internal and external validity of studies estimating the clinical impact of infections caused by the priority antibiotic resistant pathogens monitored by the WHO Global Antimicrobial Resistance Surveillance System. DATA SOURCES: Ovid MEDLINE, January 1950 to March 2019, In-Process and other non-indexed citations were searched. STUDY ELIGIBILITY CRITERIA: Studies reporting mortality, length of hospital stay, duration of the disease until remission and/or death, complications, hospital re-admissions, and follow-up beyond hospital discharge were eligible. METHODS: The literature was searched according to the Cochrane recommendations and reported according to Preferred Reporting Items for Systematic Reviews. RESULTS: Two-hundred and eighty-six studies out of 3529 were eligible. Studies derived mainly from high-income countries (215, 75%) and relied on data from retrospective (226, 79%), single-centre (201, 70%), cohort studies (243, 85%). The health impact was mostly limited to all-cause mortality (128, 45%) with heterogeneity in timing of assessment; attributable length of hospital stay was seldom adjusted for pre-infection admission time and a few studies had enough follow-up for assessing long-term sequelae. Overall, adjustment for confounding has shown a substantial improvement. Data on health state definitions and duration of diseases are generally lacking, precluding calculation of disability-adjusted life years, critical for application of the GBD study methodology. CONCLUSION: Efforts to improve harmonization, representativeness, quality of AMR surveillance data and cohort studies to determine AMR attributable mortality and morbidity are urgently required. Policy makers need accurate and detailed burden estimates to inform prioritization of resource allocation, and to select the most effective intervention strategies to halt the AMR crisis.
引用
- Pezzani MD, Tornimbene B, Pessoa-Silva C, et al. Methodological quality of studies evaluating the burden of drug-resistant infections in humans due to the WHO Global Antimicrobial Resistance Surveillance System target bacteria. Clin Microbiol Infect. 2021. PMID: 33450389. doi:10.1016/j.cmi.2021.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。